Nov 8, 2006
Nathan Klein is the first person in the world to receive gene therapy in the brain to reduce the devastating effects of this disease. This research represents a significant step towards refining effective gene therapies to treat not only Parkinson's, but other neurological disorders – and could someday offer new hope to others with this debilitating disease. With over 700 ongoing clinical trials, NewYork-Presbyterian Hospital and the medical colleges of Weill Cornell and Columbia University collaborate to find answers that enhance and save lives. NewYork-Presbyterian is one of only five hospitals in the country ranked in all 16 specialties reviewed by U.S.News & World Report. To learn more, call 877-NYP-WELL, or visit nyp.org. Don't you deserve this level of care?
- Genes isolated by Columbia researchers may explain 74% of age-related macular degeneration cases.
- New incision-free technique for colorectal cancer surgery pioneered by NewYork-Presbyterian/Weill Cornell surgeons.
- NewYork-Presbyterian/Columbia physician develops potential nonsurgical alternative to mitral valve repair.
- NewYork-Presbyterian/Columbia physician leads clinical trial to maximize effects of biventricular pacemakers and optimize cardiac output in patients with acute heart failure.
- Weill Cornell scientists first to utilize technique to prevent genetic eye cancer in newborns.
- Columbia researchers discover that a cancer-causing protein stimulates regeneration in nerve cells damaged by neurological disease or spinal cord injury.
- Physicians at NewYork-Presbyterian/Weill Cornell improve removal of stroke-inducing blood clots from brain with use of corkscrew-like device.
- NewYork-Presbyterian/Columbia physicians lead landmark trial demonstrating carotid stenting safe for patients with asymptomatic carotid artery disease.
- Researchers at NewYork-Presbyterian/Weill Cornell discover that use of IVIg antibodies improves long-term cognitive ability of Alzheimer's patients.
- Morgan Stanley Children's Hospital physician/scientist leads international study to find less toxic treatment for children with cancer.
- NewYork-Presbyterian/Weill Cornell physician/scientists lead study concluding that current triple-drug regimens effectively treat large majority of HIV patients.
- Physicians at NewYork-Presbyterian/Columbia lead study to confirm that noninvasive gene expression testing from routine blood work can detect heart transplant rejection.
- NewYork-Presbyterian/Weill Cornell first in U.S. to offer promising chemotherapy cocktail to achieve long-term survival for some bone marrow cancer patients.
- Protein in nerve cells discovered to be "on/off switch" for chronic pain by Columbia researchers.
- NewYork-Presbyterian/Weill Cornell surgeons among first to implant new stents designed for use in delicate brain vessels.